<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are initiated by mutations of APC, leading to increased β-catenin-mediated signaling </plain></SENT>
<SENT sid="1" pm="."><plain>However continued requirement of Wnt/β-catenin signaling for <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in the context of acquired KRAS and other mutations is less well established </plain></SENT>
<SENT sid="2" pm="."><plain>To attenuate Wnt/β-catenin signaling in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, we have developed potent and specific small-molecule tankyrase inhibitors, G007-LK and G244-LM, that reduce Wnt/β-catenin signaling by preventing poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="0" ids="26565">ribosyl</z:chebi>)ation-dependent AXIN degradation, thereby promoting β-catenin destabilization </plain></SENT>
<SENT sid="3" pm="."><plain>We show that novel tankyrase inhibitors completely block ligand-driven Wnt/β-catenin signaling in cell culture and display approximately 50% inhibition of APC-mutation-driven signaling in most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>It was previously unknown whether the level of AXIN protein stabilization by tankyrase inhibition is sufficient to impact <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in the absence of <z:mpath ids='MPATH_458'>normal</z:mpath> APC activity </plain></SENT>
<SENT sid="5" pm="."><plain>Compound G007-LK displays favorable pharmacokinetic properties and inhibits in vivo <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in a subset of APC-mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> most sensitive to tankyrase inhibitor, COLO-320DM, G007-LK inhibits cell cycle progression, reduces colony formation, and induces differentiation, suggesting that β-catenin-dependent maintenance of an undifferentiated state may be blocked by tankyrase inhibition </plain></SENT>
<SENT sid="7" pm="."><plain>The full potential of G007-LK's anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity may be limited by intestinal toxicity associated with inhibition of Wnt/β-catenin signaling and cell proliferation in intestinal crypts </plain></SENT>
<SENT sid="8" pm="."><plain>These results establish proof-of-concept anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> efficacy for tankyrase inhibitors in APC-mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> models, and uncover potential diagnostic and safety concerns to be overcome as tankyrase inhibitors are advanced into the clinic </plain></SENT>
</text></document>